CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 800 target
Drug / intervention
Third-generation EGFR-TKI +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04324164
NCT04324164N/ARecruitingUpdate OverdueUpdated 17mo ago · Completion was 6mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Hunan Province Tumor Hospital·observational·Posted Mar 27, 2020·Updated Jan 27, 2025

In Brief

An observational study evaluating Third-generation EGFR-TKI and EGFR-TKI for Non-small Cell Lung Cancer. Currently recruiting, targeting 800 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

N/ARecruiting
20212022202320242025202620272028
First PostedMar 27, 2020
Enrollment StartMar 24, 2020
Primary CompletionDec 24, 2025
Study CompletionDec 24, 2027
TodayJul 1, 2026
Enrollment to primary: 5.8 yearsPosted 6.3 years ago

Interventions

Third-generation EGFR-TKIdrug

Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

EGFR-TKIdrug

All EGFR-TKI